HomeAI · summaries
Storia in 2 fonti
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Akeso, Summit drug extends survival in closely watched lung cancer trial
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies…
- ·
morningstar.com
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in…
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to…
- ·
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion…
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in…
- ·
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced…
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
- ·
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026